A Current Practice Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous Blood Stem Cell Transplantation for High Risk Lymphoma or Hodgkin's Disease
Phase of Trial: Phase IV
Latest Information Update: 26 Dec 2018
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Autologous stem cell therapy; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Hodgkin's disease; Lymphoma
- Focus Therapeutic Use
- Acronyms Rituxan+BEAM
- 29 Nov 2018 Status changed from active, no longer recruiting to completed.
- 25 Sep 2015 Planned End Date changed from 1 Oct 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov reecord.
- 29 Oct 2012 New trial record